A single‐centre, real‐world study on the efficacy and recovery of inflammatory cytokine levels of C5 complement inhibitor therapy in patients with paroxysmal nocturnal haemoglobinuria
British Journal of Haematology · 2025
DOI: 10.1111/bjh.70156 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Mengting Che und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Tianjin Medical University General Hospital, Tianjin, PR China. Hauptthemen laut MEDLINE: Hemoglobinuria, Paroxysmal, Complement C5, Cytokines, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Tianjin Municipal Natural Science Foundation, Tianjin Key Medical Discipline (Specialty) Construction Project.
Abstract (Originalsprache)
Paroxysmal nocturnal haemoglobinuria (PNH) is a rare clonal disorder caused by PIG‐A mutations and characterized by complement‐mediated haemolysis. C5 inhibitors are recommended as first‐line therapy for PNH with high disease activity. We retrospectively analysed 57 patients treated with eculizumab or crovalimab. Luminex® liquid‐phase chip technology was used to detect changes in complement and cytokine levels in patients pre‐ and post‐treatment. Haemolysis control (LDH ≤ 1.5 × ULN) was achieved in 78.9% of patients, and 68.3% became transfusion‐independent. Mean haemoglobin rose from 76 to 99 g/L at week 24. Infections were the most common adverse events, but none were severe, and no discontinuations occurred. Post‐treatment, C5 and C5a levels increased significantly. Baseline levels of C5, C5a, C3, C1q, granulocyte colony‐stimulating factor (G‐CSF) and tumour necrosis factor‐α (TNF‐α) were higher in non‐responders than in responders or controls. Our findings confirm the efficacy and safety of C5 inhibitors in Chinese PNH patients and indicate that complement and cytokine profiles may serve as predictive biomarkers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Tianjin Medical University General Hospital, Tianjin, PR China.
- Tianjin Key Laboratory of Bone Marrow Failure and Malignant Hemopoietic Clone Control, Tianjin, PR China.
- Tianjin Institute of Hematology, Tianjin, PR China.
ORCID-Profile: Mengting Che, Chaomeng Wang, Yongchun Li, Liyan Li, Yingying Chen, Zhaoyun Liu, Lijuan Li, Hui Liu, Rong Fu
Förderung
- National Natural Science Foundation of China
- Tianjin Municipal Natural Science Foundation
- Tianjin Key Medical Discipline (Specialty) Construction Project
- Tianjin Municipal Commission of Education Research Project
- Natural Science Foundation of Tianjin Municipality
Zitieren
APA
Che, M., Wang, C., Li, Y., Li, L., Wang, H., Chen, Y., Liu, Z., Li, L., Liu, H., & Fu, R. (2025). A single‐centre, real‐world study on the efficacy and recovery of inflammatory cytokine levels of C5 complement inhibitor therapy in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology. https://doi.org/10.1111/bjh.70156
Vancouver
Che M, Wang C, Li Y, Li L, Wang H, Chen Y, et al. A single‐centre, real‐world study on the efficacy and recovery of inflammatory cytokine levels of C5 complement inhibitor therapy in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology. 2025. doi:10.1111/bjh.70156
BibTeX
@article{Che2025,
author = {Che, Mengting and Wang, Chaomeng and Li, Yongchun and Li, Liyan and Wang, Honglei and Chen, Yingying and Liu, Zhaoyun and Li, Lijuan and Liu, Hui and Fu, Rong},
title = {A single‐centre, real‐world study on the efficacy and recovery of inflammatory cytokine levels of C5 complement inhibitor therapy in patients with paroxysmal nocturnal haemoglobinuria},
journal = {British Journal of Haematology},
year = {2025},
doi = {10.1111/bjh.70156}
}
EUVIMED